Day-28 complete response occurred in 54/78 B-ALL patients, with MRD negativity in 83.3% of responders and median OS 13.6 ...

Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute. In vivo CAR T-cell therapy could drastically ...

CAR T-cell therapy re-engineers immune cells to target and eradicate high-risk blood cancers, offering potential cures where traditional chemotherapy fails. Initially requiring inpatient care due to ...

A technique that transforms immune cells into cancer-seeking bloodhounds may overcome a roadblock that has hampered immunotherapy for solid tumors, according to a new study by Stanford Medicine ...

The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a ...

Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has ...

BCMA CAR T approvals (ide-cel 2021; cilta-cel 2022) deliver near-98% response in trials but require specialized centers, creating logistical constraints on access. Across >9 million UC patients, ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...

For patients who have spent years managing unpredictable and debilitating autoimmune conditions like lupus, the findings ...

The curious minds at ColdFusion break down CAR-T therapy designed to target and kill cancer cells. Republicans pull off shock result in Virginia special election Contributor: Ukraine's aid against ...

Doctors at the University of Washington and Fred Hutch Cancer Center have better characterized an emerging complication of chimeric antigen receptor (CAR) T-cell therapy. A recent paper in Movement ...

Stylus Medicine, a member of BioSpace’s NextGen Class of 2026, launched in May 2025 to develop new, less complex genetic medicines. The company’s in vivo approach has attracted “intense” interest from ...